Biotech takes a Christmas beating after safety fears force researchers to halt all hep B studies
There’s no place to run, no place to hide when a critical failure occurs. That includes Christmas break.
Spring Bank Pharmaceuticals $SBPH took a beating Thursday morning after announcing that investigators had spotted safety problems with their Phase IIb study for their hepatitis B therapy, inarigivir soproxil 400mg. They’re stopping dosing for all trials after noting that 3 patients experienced “hepatocellular dysfunction and an elevation of alanine transaminase (ALT) potentially consistent with liver injury rather than immune flares.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.